Treatment Patterns in US Patients Hospitalized With COVID-19 and Pulmonary Involvement.
Identifieur interne : 000070 ( Main/Corpus ); précédent : 000069; suivant : 000071Treatment Patterns in US Patients Hospitalized With COVID-19 and Pulmonary Involvement.
Auteurs : Jennie H. Best ; Amanda M. Kong ; Emma Kaplan-Lewis ; Otis W. Brawley ; Rachel Baden ; James L. Zazzali ; Karen S. Miller ; James Loveless ; Krutika Jariwala-Parikh ; Shalini V. MohanSource :
- Journal of medical virology [ 1096-9071 ] ; 2021.
Abstract
This study describes the baseline characteristics and treatment patterns of US patients hospitalized with a diagnosis of coronavirus disease 2019 (COVID-19) and pulmonary involvement. Patients hospitalized with pulmonary involvement due to COVID-19 (first hospitalization) were identified in the IBM Explorys® electronic health records database. Demographics, baseline clinical characteristics, and in-hospital medications were assessed. For evaluation of in-hospital medications, results were stratified by race, geographic region, age and month of admission. Of 6564 hospitalized patients with COVID-19-related pulmonary involvement, 50.4% were male, and mean (SD) age was 62.6 (16.4) years; 75.2% and 23.6% of patients were from the South and Midwest, respectively, and 50.2% of patients were African American. Compared with African American patients, a numerically higher proportion of White patients received dexamethasone (19.7% vs 31.8%, respectively), nonsteroidal anti-inflammatory drugs (NSAIDs; 27.1% vs 34.9%), bronchodilators (19.8% vs 29.5%), and remdesivir (9.3% vs 21.0%). Numerically higher proportions of White patients than African American patients received select medications in the South but not in the Midwest. Compared with patients in the South, a numerically higher proportion of patients in the Midwest received dexamethasone (20.1% vs 34.5%, respectively), NSAIDs (19.6% vs 55.7%), bronchodilators (15.9% vs 41.3%), and remdesivir (10.6% vs 23.1%). Inpatient use of hydroxychloroquine decreased over time, whereas use of dexamethasone and remdesivir increased over time. Among US patients predominantly from the South and Midwest hospitalized with COVID-19 and pulmonary involvement, differences were seen in medication use between different races, geographic regions, and months of hospitalization. This article is protected by copyright. All rights reserved.
DOI: 10.1002/jmv.27049
PubMed: 33913536
Links to Exploration step
pubmed:33913536Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment Patterns in US Patients Hospitalized With COVID-19 and Pulmonary Involvement.</title><author><name sortKey="Best, Jennie H" sort="Best, Jennie H" uniqKey="Best J" first="Jennie H" last="Best">Jennie H. Best</name><affiliation><nlm:affiliation>Genentech, Inc, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kong, Amanda M" sort="Kong, Amanda M" uniqKey="Kong A" first="Amanda M" last="Kong">Amanda M. Kong</name><affiliation><nlm:affiliation>IBM Watson Health, Cambridge, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kaplan Lewis, Emma" sort="Kaplan Lewis, Emma" uniqKey="Kaplan Lewis E" first="Emma" last="Kaplan-Lewis">Emma Kaplan-Lewis</name><affiliation><nlm:affiliation>NYC Health and Hospitals, Elmhurst Hospital Center, Queens, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Brawley, Otis W" sort="Brawley, Otis W" uniqKey="Brawley O" first="Otis W" last="Brawley">Otis W. Brawley</name><affiliation><nlm:affiliation>Johns Hopkins Medicine, Baltimore, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Baden, Rachel" sort="Baden, Rachel" uniqKey="Baden R" first="Rachel" last="Baden">Rachel Baden</name><affiliation><nlm:affiliation>Department of Medicine, Alameda Health System-Highland Hospital, Oakland, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zazzali, James L" sort="Zazzali, James L" uniqKey="Zazzali J" first="James L" last="Zazzali">James L. Zazzali</name><affiliation><nlm:affiliation>Genentech, Inc, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Miller, Karen S" sort="Miller, Karen S" uniqKey="Miller K" first="Karen S" last="Miller">Karen S. Miller</name><affiliation><nlm:affiliation>St. Luke's Health System, Boise, ID, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Loveless, James" sort="Loveless, James" uniqKey="Loveless J" first="James" last="Loveless">James Loveless</name><affiliation><nlm:affiliation>St. Luke's Health System, Boise, ID, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Jariwala Parikh, Krutika" sort="Jariwala Parikh, Krutika" uniqKey="Jariwala Parikh K" first="Krutika" last="Jariwala-Parikh">Krutika Jariwala-Parikh</name><affiliation><nlm:affiliation>IBM Watson Health, Cambridge, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mohan, Shalini V" sort="Mohan, Shalini V" uniqKey="Mohan S" first="Shalini V" last="Mohan">Shalini V. Mohan</name><affiliation><nlm:affiliation>Genentech, Inc, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33913536</idno><idno type="pmid">33913536</idno><idno type="doi">10.1002/jmv.27049</idno><idno type="wicri:Area/Main/Corpus">000070</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000070</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment Patterns in US Patients Hospitalized With COVID-19 and Pulmonary Involvement.</title><author><name sortKey="Best, Jennie H" sort="Best, Jennie H" uniqKey="Best J" first="Jennie H" last="Best">Jennie H. Best</name><affiliation><nlm:affiliation>Genentech, Inc, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kong, Amanda M" sort="Kong, Amanda M" uniqKey="Kong A" first="Amanda M" last="Kong">Amanda M. Kong</name><affiliation><nlm:affiliation>IBM Watson Health, Cambridge, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kaplan Lewis, Emma" sort="Kaplan Lewis, Emma" uniqKey="Kaplan Lewis E" first="Emma" last="Kaplan-Lewis">Emma Kaplan-Lewis</name><affiliation><nlm:affiliation>NYC Health and Hospitals, Elmhurst Hospital Center, Queens, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Brawley, Otis W" sort="Brawley, Otis W" uniqKey="Brawley O" first="Otis W" last="Brawley">Otis W. Brawley</name><affiliation><nlm:affiliation>Johns Hopkins Medicine, Baltimore, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Baden, Rachel" sort="Baden, Rachel" uniqKey="Baden R" first="Rachel" last="Baden">Rachel Baden</name><affiliation><nlm:affiliation>Department of Medicine, Alameda Health System-Highland Hospital, Oakland, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zazzali, James L" sort="Zazzali, James L" uniqKey="Zazzali J" first="James L" last="Zazzali">James L. Zazzali</name><affiliation><nlm:affiliation>Genentech, Inc, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Miller, Karen S" sort="Miller, Karen S" uniqKey="Miller K" first="Karen S" last="Miller">Karen S. Miller</name><affiliation><nlm:affiliation>St. Luke's Health System, Boise, ID, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Loveless, James" sort="Loveless, James" uniqKey="Loveless J" first="James" last="Loveless">James Loveless</name><affiliation><nlm:affiliation>St. Luke's Health System, Boise, ID, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Jariwala Parikh, Krutika" sort="Jariwala Parikh, Krutika" uniqKey="Jariwala Parikh K" first="Krutika" last="Jariwala-Parikh">Krutika Jariwala-Parikh</name><affiliation><nlm:affiliation>IBM Watson Health, Cambridge, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mohan, Shalini V" sort="Mohan, Shalini V" uniqKey="Mohan S" first="Shalini V" last="Mohan">Shalini V. Mohan</name><affiliation><nlm:affiliation>Genentech, Inc, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of medical virology</title><idno type="eISSN">1096-9071</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study describes the baseline characteristics and treatment patterns of US patients hospitalized with a diagnosis of coronavirus disease 2019 (COVID-19) and pulmonary involvement. Patients hospitalized with pulmonary involvement due to COVID-19 (first hospitalization) were identified in the IBM Explorys® electronic health records database. Demographics, baseline clinical characteristics, and in-hospital medications were assessed. For evaluation of in-hospital medications, results were stratified by race, geographic region, age and month of admission. Of 6564 hospitalized patients with COVID-19-related pulmonary involvement, 50.4% were male, and mean (SD) age was 62.6 (16.4) years; 75.2% and 23.6% of patients were from the South and Midwest, respectively, and 50.2% of patients were African American. Compared with African American patients, a numerically higher proportion of White patients received dexamethasone (19.7% vs 31.8%, respectively), nonsteroidal anti-inflammatory drugs (NSAIDs; 27.1% vs 34.9%), bronchodilators (19.8% vs 29.5%), and remdesivir (9.3% vs 21.0%). Numerically higher proportions of White patients than African American patients received select medications in the South but not in the Midwest. Compared with patients in the South, a numerically higher proportion of patients in the Midwest received dexamethasone (20.1% vs 34.5%, respectively), NSAIDs (19.6% vs 55.7%), bronchodilators (15.9% vs 41.3%), and remdesivir (10.6% vs 23.1%). Inpatient use of hydroxychloroquine decreased over time, whereas use of dexamethasone and remdesivir increased over time. Among US patients predominantly from the South and Midwest hospitalized with COVID-19 and pulmonary involvement, differences were seen in medication use between different races, geographic regions, and months of hospitalization. This article is protected by copyright. All rights reserved.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">33913536</PMID><DateRevised><Year>2021</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>Apr</Month><Day>29</Day></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Treatment Patterns in US Patients Hospitalized With COVID-19 and Pulmonary Involvement.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.27049</ELocationID><Abstract><AbstractText>This study describes the baseline characteristics and treatment patterns of US patients hospitalized with a diagnosis of coronavirus disease 2019 (COVID-19) and pulmonary involvement. Patients hospitalized with pulmonary involvement due to COVID-19 (first hospitalization) were identified in the IBM Explorys® electronic health records database. Demographics, baseline clinical characteristics, and in-hospital medications were assessed. For evaluation of in-hospital medications, results were stratified by race, geographic region, age and month of admission. Of 6564 hospitalized patients with COVID-19-related pulmonary involvement, 50.4% were male, and mean (SD) age was 62.6 (16.4) years; 75.2% and 23.6% of patients were from the South and Midwest, respectively, and 50.2% of patients were African American. Compared with African American patients, a numerically higher proportion of White patients received dexamethasone (19.7% vs 31.8%, respectively), nonsteroidal anti-inflammatory drugs (NSAIDs; 27.1% vs 34.9%), bronchodilators (19.8% vs 29.5%), and remdesivir (9.3% vs 21.0%). Numerically higher proportions of White patients than African American patients received select medications in the South but not in the Midwest. Compared with patients in the South, a numerically higher proportion of patients in the Midwest received dexamethasone (20.1% vs 34.5%, respectively), NSAIDs (19.6% vs 55.7%), bronchodilators (15.9% vs 41.3%), and remdesivir (10.6% vs 23.1%). Inpatient use of hydroxychloroquine decreased over time, whereas use of dexamethasone and remdesivir increased over time. Among US patients predominantly from the South and Midwest hospitalized with COVID-19 and pulmonary involvement, differences were seen in medication use between different races, geographic regions, and months of hospitalization. This article is protected by copyright. All rights reserved.</AbstractText><CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Best</LastName><ForeName>Jennie H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-4616-5703</Identifier><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Amanda M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-6210-4185</Identifier><AffiliationInfo><Affiliation>IBM Watson Health, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaplan-Lewis</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>NYC Health and Hospitals, Elmhurst Hospital Center, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brawley</LastName><ForeName>Otis W</ForeName><Initials>OW</Initials><AffiliationInfo><Affiliation>Johns Hopkins Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baden</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Alameda Health System-Highland Hospital, Oakland, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zazzali</LastName><ForeName>James L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>St. Luke's Health System, Boise, ID, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loveless</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>St. Luke's Health System, Boise, ID, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jariwala-Parikh</LastName><ForeName>Krutika</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>IBM Watson Health, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>Shalini V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>29</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33913536</ArticleId><ArticleId IdType="doi">10.1002/jmv.27049</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000070 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000070 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33913536
|texte= Treatment Patterns in US Patients Hospitalized With COVID-19 and Pulmonary Involvement.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33913536" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |